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Abstract
Available evidence on the bioactive, nutritional and putative detrimental properties of gut microbial metabolites has been evaluated to sup-
port a more integrated view of how prebiotics might affect host health throughout life. The present literature inventory targeted evidence
for the physiological and nutritional effects of metabolites, for example, SCFA, the potential toxicity of other metabolites and attempted to
determine normal concentration ranges. Furthermore, the biological relevance of more holistic approaches like faecal water toxicity assays
and metabolomics and the limitations of faecal measurements were addressed. Existing literature indicates that protein fermentation metab-
olites (phenol, p-cresol, indole, ammonia), typically considered as potentially harmful, occur at concentration ranges in the colon such that
no toxic effects are expected either locally or following systemic absorption. The endproducts of saccharolytic fermentation, SCFA, may
have effects on colonic health, host physiology, immunity, lipid and protein metabolism and appetite control. However, measuring
SCFA concentrations in faeces is insufficient to assess the dynamic processes of their nutrikinetics. Existing literature on the usefulness
of faecal water toxicity measures as indicators of cancer risk seems limited. In conclusion, at present there is insufficient evidence to
use changes in faecal bacterial metabolite concentrations as markers of prebiotic effectiveness. Integration of results from metabolomics
and metagenomics holds promise for understanding the health implications of prebiotic microbiome modulation but adequate tools for
data integration and interpretation are currently lacking. Similarly, studies measuring metabolite fluxes in different body compartments
to provide a more accurate picture of their nutrikinetics are needed.
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Introduction
For a long time, the colon was considered as an organ
that merely absorbs water and electrolytes and converts
undigested food residues to drive their excretion without
having important physiological functions. Nowadays, it
has been generally recognised that the microbial ecosys-
tem inhabiting the gut profoundly affects human
physiology and health. The gut bacteria can be considered
as a highly active metabolic organ that provides metabolic
traits that complement those encoded within our own
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genome. For instance, degradation of several structural
polysaccharides in plant cell walls requires enzymes that
are not encoded by the host but are available in specific
bacteria(1). The collective genetic information encoded in
the intestinal micro-organisms is truly impressive and has
been referred to as ‘our other genome’(2).
The metabolites produced by the gut bacteria are
accessible to the host’s cells and in this way influence
physiological processes both locally in the intestine and
systemically. They contribute to the metabolic phenotype
of the host and hence may influence the risk of disease(3).
Undigested carbohydrate and protein constitute the major
substrates at the disposal of the microbiota for fer-
mentation and result in the production of a range of
well-established metabolites including SCFA, branched-
chain fatty acids (BCFA), ammonia, amines, phenolic
compounds and gases including hydrogen, methane and
hydrogen sulfide. Other metabolic activities include the
activation or inactivation of bioactive food components
like isoflavanoids, flavanoids and plant lignans, the conver-
sion of pro-drugs to drugs, the production of vitamins and
the transformation of bile acids and xenobiotics(4,5).
Although the fermentative and metabolic activity in the
human intestine has been studied for many decades, it
remains difficult to evaluate bacterial metabolism in the
colon in vivo. Most studies have relied on analysis of the
composition of faeces, in vitro incubation studies using
faecal inocula or experimental animal models.
An imbalance in the composition of the microbiota has
been increasingly associated with the occurrence of
chronic or lifestyle-related diseases such as inflammatory
bowel disease (IBD), obesity and type 2 diabetes as well
as with certain autoimmune diseases such as type 1 dia-
betes, coeliac disease or allergic asthma(6). Therefore,
manipulation of the microbiota has become a promising
target for the improvement of host health. As diet is a
major factor driving the composition and metabolism of
the colonic microbiota, dietary interventions that modulate
the supply of macronutrients (carbohydrates, proteins, fat)
to the colon have been extensively investigated for this
purpose. In particular prebiotics, defined as ‘selectively fer-
mented food ingredients that allow specific changes in
composition and/or activity of the microbiota that confer
benefits upon host well-being and health’(7), have been
used in an attempt to improve gut health and by extension
systemic health (http://www.worldgastroenterology.org/
probiotics-prebiotics). Previously, the effect of prebiotic
supplementation has been measured using the relative
increase in Bifidobacterium and Lactobacillus species as
markers(8). However, increasing knowledge on the intesti-
nal microbiota has shown that other genera or species may
also confer health benefits, expanding the potential role of
prebiotics. Emerging genera that may play a role in the
maintenance of intestinal homeostasis and health include
Eubacterium, Faecalibacterium, Roseburia and some
species of Clostridia (7). Since the microbiota is characterised
by a significant degree of functional redundancy(9), meaning
that different bacteria are able to perform similar functions,
metabolise the same substrates and produce similar metab-
olites, analysing the activity of the microbiota rather than
its composition and structure may be more relevant to
assess the impact of prebiotic interventions.
In the present review, we have re-evaluated our current
understanding of the role of bacterial metabolites in pro-
moting or reducing health to estimate the potential applica-
bility of those metabolites as markers of improved/reduced
gut health. Moreover, we recognise that the contribution of
the microbiota to the overall mammalian biochemistry may
play distinctive roles at different developmental stages of
the host. We have identified the limitations associated
with analysis of single metabolites and have evaluated
the usefulness of more holistic approaches including func-
tional analysis of faecal water, metabolomics and metagen-
ome analysis. The ultimate goal is to move towards
a definition of ‘healthy metabolic signatures’ that might
comprise integrated measures of metabolite patterns in
different matrices.
Metabolites produced by microbial fermentation
The complex microbial ecosystem inhabiting the human
intestinal tract produces a wide range of metabolites that
interact with the host’s cells and in this way influence the
physiological processes in the colon. In addition, the
metabolites may be absorbed and influence the overall
mammalian biochemistry, thereby eliciting systemic effects.
Table 1 provides an overview of the major bacterial com-
pounds that can be found in the intestine.
From this list of compounds, we selected a subset of
metabolites that were considered relevant to improved or
decreased health. Most of those metabolites are so-called
primary metabolites which comprise products of
metabolism that are essential for growth or that are the
by-products of energy-yielding metabolism. Secondary
metabolites (products which do not have an obvious role
in cell metabolism such as vitamins) were not included
for further analysis. The metabolites reviewed here include
products of carbohydrate fermentation (acetic, propionic
and butyric acid as well as lactic acid and succinic acid)
and products of protein metabolism (ammonia, BCFA,
phenol, amines, p-cresol, indole and hydrogen sulfide).
In addition, metabolites of plant polyphenols have been
included because of their putative health benefits and
their bidirectional interaction with the intestinal
microbiota.
Beneficial and harmful effects of relevant metabolites
Products of carbohydrate fermentation
SCFA. SCFA are mainly produced in the colon by bac-
terial fermentation of carbohydrates that escaped digestion
Microbial metabolites and prebiotic benefits 43
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in the small intestine. They are saturated aliphatic organic
acids consisting of one to six carbons of which acetate
(C2), propionate (C3) and butyrate (C4) are the most abun-
dant ($95 %)(10,11). SCFA production mainly occurs in the
proximal part of the colon where the availability of
substrates is most abundant. The majority of SCFA (up to
95 %) are rapidly absorbed by the colonocytes resulting
in decreasing concentrations from the proximal to distal
colon. Only a minor fraction of SCFA (about 5 %) is
excreted in faeces(12).
Due to the inaccessibility of the human proximal colon
for direct investigation and the rapid absorption of SCFA
from the colonic lumen, it is extremely difficult to quantify
SCFA production rates. Consequently, no systematic evalu-
ation of normal ‘healthy’ production of SCFA is available.
Assuming that 50–60 g carbohydrates reach the colon
per d, the production of SCFA was estimated at 400–600
mmol/d(10). Most studies measure faecal SCFA which are
the resultant of their production and absorption. Therefore,
faecal SCFA rather indicate losses and do not adequately
reflect in situ production rates. Table 2 provides an over-
view of reported values in the literature for total and indi-
vidual faecal SCFA in adults. Faecal excretion of total SCFA
ranges from 60 to 90 mmol/g and might be slightly higher
in obese subjects (80–100 mmol/g). SCFA are also detect-
able in urine, but are the remnant of gut, liver and systemic
metabolism and do not reflect colonic generation either. In
addition, acetate not only originates from the gut but also
from endogenous metabolism, in particular fatty acid oxi-
dation and glucose and/or amino acid metabolism(13,14).
Measurement of SCFA in plasma is similarly confounded.
Stable isotope studies are required to reliably quantify
colonic SCFA production as well as their metabolic fate
in the host organism.
The pattern and amounts of faecal SCFA change through
the different stages in life. In early infancy, the predomi-
nant SCFA are acetate and lactate in breast-fed infants
and acetate and propionate in (unsupplemented) for-
mula-fed infants(15). In infants fed a formula supplemented
with a mixture of galacto-oligosaccharides and fructo-
oligosaccharides (9:1 ratio), faecal SCFA patterns were
dominated by acetate, similarly as in breast-fed infants,
with lower proportions of propionate and butyrate com-
pared with the unsupplemented formula(16). The levels of
propionate have been reported to increase in the months
before weaning. Butyrate production increases in the
Table 1. List of bacterial metabolites that may be found in the intestine
Type of metabolite Metabolites
Metabolites derived from bacterial energy metabolism ‘Terminal’ metabolites from carbohydrate fermentation
SCFA: formate, acetate, propionate, butyrate,
longer-chain fatty acids
Branched-chain fatty acids
‘Intermediate’ metabolites from carbohydrate fermentation
Partially degraded oligomeric carbohydrates (disaccharides,
oligosaccharides, complex proteoglycans from mucins, etc.)
Alcohols: methanol, ethanol, etc.
Gaseous metabolites
Fermentation gases: hydrogen, methane, carbon dioxide
Highly volatile compounds: hydrogen sulfide
Metabolites of fatty acid and lipid bioconversion
Long-chain aldehydes
Fatty acids
Metabolites from protein fermentation
Branched-chain fatty acids
Ammonia and amines
Aromatic derivatives of amino acids: phenols, cresols, indoles, etc.
Metabolites derived from bioconversion of
plant secondary compounds
Products of lignin/polyphenols bioconversion: equol, enterolactone, etc.
Metabolites from bacterial cytosolic compartment or
secondary metabolism (spilled over by
excess production, efflux or upon cell lysis)
Vitamins and cofactors (often in very small concentrations)
Peptides (quorum-sensing signals of Gram-positive bacteria)
Homoserine lactone (quorum-sensing signals
of Gram-negative bacteria)
Nucleic acids (free DNA, microRNA, etc.)
Bacteriocins
Metabolites of the enterohepatic circulation Bile acids
Cholesterol, coprostanol
Hormones and derivatives
Glucuronide conjugates
Enzymes Reductases
Glucuronidases
Glycohydrolases
Bacterial cell wall components |(of which several are immunoactive) Lipopolysaccharide Polysaccharide A
Peptidoglycan-derived structures
Capsular polysaccharides (glycocalix)
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Table 2. Faecal concentration of individual SCFA
Subjects
(n); age
Reported
measure Acetic acid Propionic acid Butyric acid Total SCFA Unit Reference
Healthy
subjects
10; 21–34 years Mean (SD) 218 (99) 72 (37) 58·7 (54·5) 378 (188) mmol/g dry weight Whelan (2005)(236)
20; 20–40 years Mean (SEM) 320·3 (24·9) 97·3 (10·5) 93·8 (9·13) 511·4 (41·9) mmol/g dry weight Boler (2011)(111)
13; 23–58 years Median (IQR) 52·2 23·2 (13·6–37·3) 36·8 (5–128) 119·3 (64·5–197·0) mmol/g wet weight Lewis (1997)(237)
60; 18–24 years Mean (SEM) 198·4 (14·2) 55·2 (4·7) 50·5 (4·9) 304·1 mmol/g dry weight Lecerf (2012)(109)
27; 18–55 years Mean (SEM) 35·8 (2·4) 11·4 (1·2) 10·0 (1·1) 61·1 (4·4) mmol/g Reimer (2012)(238)
12; 18–65 years 48 13·98 13·31 80·91 mmol/g Fernando (2010)(239)
46; 31–66 years Mean (95 %CI) 44·7 (39·7,
50·3) females
58·6 (49·8,
69·0) males
12·3 (10·7, 14·0)
females
16·1 (13·4, 19·5)
males
11·7 (9·8, 14·0)
females
15·4 (12·1, 19·6)
males
69·5 (61·3, 78·7)
females
90·5 (76·3, 108)
males
mmol/g McOrist (2011)(240)
36 Median (IQR) 43·7 (34·0–52·2) 13·1 (9·2–18·5) 8·8 (5·2–11·5) 91·8 (73·1–107·5) mmol/g Nemoto (2012)(241)
20; 22–55 years Mean (SEM) 42·13 (3·84) 11·5 (1·19) 11·28 (1·42) 67·3 (6·22) mmol/g Tiihonen (2010)(67)
8; 31–59 years Mean (SD) NR NR NR 92·7 (33·9) mmol/g McOrist (2008)(242)
20; 23–28 years Mean (SEM) NR NR NR 78·5 (6·4) mmol/g Hylla (1998)(243)
30 Mean (SD) 50·5 (12·6) 13·6 (5·2) 14·1 (7·6) 84·6 (22·9) mmol/l Schwiertz (2010)(64)
Obese
subjects
20; 22–55 years Mean (SEM) 47·15 (3·80) 13·64 (1·34) 14·73 (1·47) 78·79 (6·19) mmol/g Tiihonen (2010)(67)
91 Mean (SD) 58·5 (19·1) 17·6 (7·6) 18·3 (9·7) 102 (33·5) mmol/l Brinkworth (2009)(63)
32; 20–65 years Mean (SEM) NR NR NR 34 (6) mmol/24 h Benassi Evans (2010)(244)
35 overweight
33 obese
Mean (SD) 56·0 (18·2)
59·8 (18·3)
18·3 (7·9)
19·3 (8·7)
18·5 (10·1)
18·1 (10·0)
98·7 (33·9)
103·9 (34·3)
mmol/l Schwiertz (2010)(64)
IQR, interquartile range; NR, not reported.
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second part of the first year of life when faecal lactate
levels fall to negligible values (CA Edwards, unpublished
results). By the age of 2 years the pattern becomes more
similar to that observed in adults(17). Fig. 1 depicts
the changes in SCFA from birth up to adulthood. In the
elderly, the microbiota changes, with higher levels of
Bacteroidetes(18), which is likely to affect SCFA production.
Nevertheless, no differences were detected in SCFA levels
in a group of French 68- to 89-year-olds compared with
a group of 30- to 46-year-olds(19). In contrast, among par-
ticipants in the pan-European project on the elderly gut
microbiota (CROWNALIFE), elderly Europeans (76 ^ 7·5
years; n 55) had lower concentrations of propionate, acet-
ate and butyrate (by 30, 35 and 21 %, respectively) com-
pared with younger adults (40 ^ 9·7 years; n 53)(20). With
these apparently contradicting results obtained in different
studies, it remains to be established what the normal
patterns of SCFA in faecal material are during different
stages of life.
After uptake in the colonocytes, a considerable part of
the SCFA is used as an energy source and is oxidised to
carbon dioxide and ketone bodies(21). The fraction that is
not consumed by the colonocytes is transported across
the basolateral membrane and reaches the liver via the
portal bloodstream. Acetate is used by the liver as a
precursor for the synthesis of cholesterol and long-chain
fatty acids(22). However, in individuals following a
Western-type diet, high in refined carbohydrates, sugars
and fatty acids and low in fibre, colonic acetate is likely
to contribute only little to hepatic lipogenesis. A recent
study in obese individuals even showed an inverse associ-
ation between serum acetate levels and visceral adipose
tissue(23). In mice, it was shown that acetate derived from
colonic fermentation of fermentable carbohydrates crosses
the blood–brain barrier and directly suppresses appetite
through central hypothalamic mechanisms(24). Propionic
acid is often the second most predominant SCFA and has
received much attention for its potential roles in the
reduction of lipogenesis, cholesterol synthesis inhibition,
and more recently for its activation of G protein-coupled
receptors (GPR) 41 and GPR43, release of satiety hormones
and other metabolic and anti-inflammatory effects(25–27).
Butyric acid has been studied for its ability to promote
colonic healing in colitis(28) and its potential anti-cancer
effects(29), including apoptosis stimulation(30), in part by
inhibiting histone de-acetylase(31). It has also been shown
to inhibit oxidative damage in cultured cancer cells(32)
and it may improve gut barrier function(33). Recent studies
in mice have shown that oral administration of propionate
and butyrate, but not acetate, facilitates the extra-thymic de
novo generation of anti-inflammatory regulatory T (Treg)
cells. In contrast, rectal administration of acetate and pro-
pionate, but not butyrate, promoted accumulation of Treg
cells, suggesting that butyrate promotes de novo generation
but not colonic accumulation of Treg cells, whereas acetate
has an opposite activity and propionate is capable of
both(34). Furthermore, propionate and butyrate were
shown to activate intestinal gluconeogenesis (IGN),
which has beneficial effects on glucose and energy homeo-
stasis, via complementary mechanisms. Whereas butyrate
directly activates the IGN genes, propionate-mediated
induction of IGN depends on a gut–brain communication
axis involving the fatty acid receptor GPR41(35). Those ben-
eficial activities of SCFA produced in the intestine have
been shown in different animal species including labora-
tory animals and production/farm animals(36–38). However,
in human subjects the relevant body of evidence is limited
mainly because SCFA are traditionally only measured in
faeces or fasting blood samples.
In vitro fermentation studies with prebiotics or dietary
fibre have consistently resulted in increased levels of
SCFA. In contrast, several human prebiotic intervention
studies failed to demonstrate increased faecal SCFA, most
likely due to the rapid colonic absorption of the SCFA, pre-
venting them from being excreted in faeces(39–44). The
relative proportions of the SCFA vary between individuals
and are particularly sensitive to the type of carbohydrate
being fermented(45,46). For example, the proportion of pro-
pionic acid production is increased during fermentation of
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Fig. 1. Evolution of faecal SCFA as a function of age: acetic acid (a); propio-
nic acid (b); butyric acid (c). The arrows roughly indicate the change from
breast-feeding to solid food with concurrent successional development of the
gut microbiota away from one dominated by the bifidobacteria, which pro-
duce acetate and lactate during carbohydrate fermentation, to a more com-
plex microbiota with higher relative abundance of Firmicutes, which produce
acetate, propionate and butyrate as major SCFA endproducts of carbo-
hydrate fermentation. The figures summarises the data reported in several
studies(15,17,71,84,126,228–235). A colour version of this figure can be found
online at http://www.journals.cambridge.org/nrr
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guar gum, long-chain arabinoxylans, oats and oat fractions
(oat bran and b-glucan), pectin, pulses, wheat dextrin and
pyrodextrins(47–56) whereas oligofructose predominantly
yields acetate(57). In contrast, the proportion of butyrate
production increases with fermentation of starch and
inulin-type fructans and often results from secondary
fermentation of lactate and acetate, so-called cross-feeding
between bacteria(58). Indeed, this type of microbial cross-
feeding could be viewed as an important physiological
function supporting microbiota homeostasis and species
richness, which have both been associated with gut
health. In view of the different effects of acetic, propionic
and butyric acids, the relative proportions of the acids
produced are probably as relevant as their total levels.
Several animal and human studies have recently demon-
strated an association between the gut microbiota compo-
sition and obesity. Initial studies found with a higher
Firmicutes:Bacteroidetes ratio in the obese(59,60). A greater
fermentation capacity in both obese animals and human
subjects compared with normal-weight subjects was
suggested(61–63) as well as increased concentrations of
caecal or faecal SCFA. It was therefore hypothesised that
the efficiency of the energy harvest from food was
increased in obesity. However, later studies demonstrated
that in human subjects, the relationship between the Firmi-
cutes:Bacteroidetes ratio and obesity is less clear and
human obesity may be associated with more subtle
changes in the microbiota composition(64,65). In a recent
metagenomic study the typical ecological entity of micro-
biota ‘richness’ was highlighted as a strong determinant
in body-weight control rather than its composition per
se (66). Reported levels of faecal SCFA in obese subjects
were higher than in normal-weight subjects (Table 2),
although this has not been confirmed in all studies to
date(67,68). In addition, increased faecal SCFA levels do
not necessarily indicate higher absorption rates and
increased energy harvest by the host. Indeed, uptake of
SCFA in colonocytes via the monocarboxylate transporter
1 (MCT-1) receptor is induced by fibre feeding (pectin)
and butyrate, and moreover, inhibited by bile acids. There-
fore, SCFA absorption might be reduced in the obese(69,70).
Fermentation capacity can be evaluated as in vitro pro-
duction of SCFA from carbohydrates using faeces from
healthy individuals and patients(71). In pH-controlled
faecal batch cultures, similar levels of SCFA were produced
from a-gluco-oligosaccharides by microbiota from obese
and lean subjects(72). Overall, the relationships between
the microbiota composition, intestinal SCFA levels and
obesity are far from being elucidated. In a nice series of
experiments in animals and human subjects, Cani and col-
leagues demonstrated how modulation of the microbiota
by prebiotics controls endogenous glucagon-like peptide
2 production and the endocannabinoid system and con-
tributes to the improvement in gut barrier function
during obesity(73–75). The direct involvement of specific
gut bacteria and/or metabolites needs to be further
investigated.
In recent studies, the intestinal bacteria have been
implicated in the development of IBD and autoimmune
diseases such as type 1 diabetes and coeliac disease.
These conditions have been consistently characterised by
a low abundance of butyrate-producing bacteria(76–80).
Functional analysis of the microbiota revealed remarkably
lower levels of faecal SCFA in IBD(81–83) whereas total
SCFA and in particular acetate were found increased in
coeliac disease(84–86). Allergic children had lower faecal
levels of propionate and butyrate than non-allergic chil-
dren(87). It remains to be explored to what extent these
aberrant SCFA patterns are causative to the disease or can
serve as markers of disease.
Lactate and succinate. Lactate and succinate are inter-
mediates in the fermentation process of carbohydrates. In
healthy conditions, they are further metabolised to acetate
or butyrate and propionate, respectively, by cross-feeding
species and do not substantially accumulate in the colonic
lumen(88). Recent evidence suggests that succinate acts as a
signal for inflammation(89). It stabilises the transcription
factor hypoxia-inducible factor-1a (HIF-1a) in activated
macrophages. When stabilised, HIF-1a up-regulates sev-
eral genes including the inflammatory cytokine IL-1b,
resulting in exacerbation of inflammation(90). In addition,
succinate acts as a ligand for GPR91, renamed SUNCR1.
In the kidney, succinate-induced activation of GPR91 is
reported to regulate the renin–angiotensin system and in
dendritic cells, succinate signalling is required for
enhanced antigen-presenting function. Increased levels of
succinate have been linked to IBD as mice undergoing
dextran sulfate sodium-induced colitis were shown to
have more succinate in their caecum and faeces(91)
whereas in colonic tissue from dextran sulfate sodium-
induced mice, succinate levels were lower than in control
mice(92). Therefore, succinate may be an ulcerogenic
agent in the gut lumen, leading to mucosal damage and
lower succinate levels in colonic tissues.
Lactate has two optical isomers, which are L-lactate and
D-lactate. L-Lactate is produced from pyruvate by the
enzyme lactate dehydrogenase during normal anaerobic
metabolism whereas D-lactate is produced by many com-
mensal bacteria in the colon. Increased levels of D-lactate
in plasma and urine have been demonstrated in
IBD(81,93), intestinal ischaemia(94), short bowel(95) and
appendicitis(96) and are considered as a marker of dysbiosis
and/or increased intestinal permeability. In faecal
samples of IBD patients, mainly L-lactate levels are
increased(80,97,98), suggesting a mucosal origin of lactate(99).
As lactate is a potentially important co-substrate for many
sulfate-reducing bacteria, increased colonic lactate levels
may promote sulfide generation(100) which is suspected
of inhibiting the b-oxidation of butyrate in the colonocytes
(see below).
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Products of protein metabolism
Microbial products from protein metabolism include
BCFA, ammonia, phenol, p-cresol, indole and hydrogen
sulfide(101). The toxic potential of these compounds is
mainly derived from in vitro experiments, in which iso-
lated cells or tissues are directly incubated with individual
compounds, or from animal studies. The present review
also encompasses the results of oral toxicity tests as a
reasonable surrogate for assessing potential systemic
effects. Minimally irritating concentrations were assessed
as a marker of local effects and exceeded 1 % for all com-
pounds, which is well above the concentrations occurring
in the colon. In human studies, there is little evidence for
adverse effects of protein fermentation metabolites(102).
In a recent study in healthy subjects, modulation of the
degree of protein fermentation by changing dietary
intake did not affect faecal water toxicity(103).
An important determinant of the degree of proteolytic
v. saccharolytic fermentation is the nutrient availability
and in particular the ratio of available carbohydrate to
nitrogen(104,105). Therefore, the production of protein
degradation products can generally be reduced by increas-
ing the amount of fermentable carbohydrate reaching the
colon in the form of resistant starch(104) or prebiotic oligo-
saccharides(106–112). In contrast, faecal ammonia, phenol
and p-cresol were not affected after 4 weeks consumption
of the polyol isomalt (30 g/d)(113).
Phenol, p-cresol and indole. The phenolic compounds
phenol, p-cresol and indole are the major metabolites of
bacterial fermentation of the aromatic amino acids tyrosine,
phenylalanine and tryptophan. These metabolites are lar-
gely and rapidly absorbed by the colonic mucosa cells
and are excreted in urine after sulfate or glucuronide con-
jugation in the mucosa or the liver(114). In healthy subjects,
these compounds do not accumulate in the body. There-
fore, their urinary elimination is often considered as a
reliable estimate of their production in the colon(105).
Many studies have reported significant interindividual
variation in the urinary excretion of p-cresol and phenol
in healthy adults. Data on ranges in other age groups
(children, elderly) are scarce. Reported mean or median
values vary between 10 and 55 mg/d for p-cresol (Table 3)
and between 4 and 7·5 mg/d for phenol (Table 4). In
obese individuals, urinary p-cresol and phenol levels at
baseline were considerably higher than those reported in
normal-weight adults (94·9 mg/d and 15·0 g/d for p-cresol
and phenol, respectively) and decreased upon weight
loss(63). The levels of urinary p-cresol may increase in the
very old(115).
Most studies on the urinary excretion of the indole
metabolite indoxyl sulfate, also called indican, report
values below 50 mg/d in healthy adults. In patients with
liver cirrhosis(116) and patients with diabetes(117), excretion
of indoxyl sulfate is higher (98·2 mg/d in cirrhosis, 65·7
mg/d in diabetics without neuropathy and 114·0 mg/d in
diabetics with neuropathy) and correlates with steator-
rhoea. In a study in patients with bladder cancer there
was no evidence that phenolic microbial metabolites had
promoting or co-carcinogenic activity for the human
urinary bladder, as the urinary excretion of p-cresol,
phenol and indoxyl sulfate was not different in the patients
as compared with controls(118).
Faecal excretion of phenolic compounds is not often
reported, but in available studies amounts of 5–8 mg/d
for p-cresol and 0·25–0·66 mg/d for phenol have been
found. Interestingly, faecal excretion of p-cresol was
4-fold higher in a group of hyperactive children as
compared with control children(119).
The effects of phenolic compounds on intestinal cells
have been determined mainly in in vitro incubation
studies. Viability of colonic epithelial cells isolated from
human biopsies was decreased after exposure to 1·25
mM-phenol, a physiologically relevant concentration,
whereas higher phenol concentrations (20 mM) were
required to reduce viability of HT-29 cells(120). Notably,
cell cultures from ulcerative colitis (UC) patients showed
similar sensitivity to phenol exposure as cell cultures
from control subjects at all concentrations tested.
Several papers have reported a concentration-dependent
increase in paracellular permeability and reduced epithelial
barrier function after incubation with phenol (1 mM to
21 mM) of Caco-2-monolayers or SK-CO15 intestinal
cells(121,122). Enhanced permeability was already apparent
at concentrations of phenol that did not cause cell death.
Similarly, p-cresol altered endothelial barrier function in
human umbilical vein endothelial cells. In chronic kidney
disease patients, p-cresol is considered a uraemic toxin.
It accumulates in serum and might participate in the endo-
thelial dysfunction that is observed in such patients(123).
The European Food Safety Authority recently evaluated
the toxicity of phenol following oral administration
(http://www.efsa.europa.eu/en/efsajournal/doc/3189.pdf)
and established a tolerable daily intake (TDI) of 0·5 mg/kg
body weight per d. For a 75 kg individual, the TDI amounts
to 37·5 mg/d, which is about 5-fold higher than the
amount of phenol generated in the colon (7·5 mg/d)
(assuming that urinary excretion rates reflect colonic
generation rates). On repeat-dose administration to non-
pregnant rats and mice, no consistent effects were seen
at doses $ 250 mg/kg body weight per d.
The Joint FAO/WHO Expert Committee on Food Addi-
tives (JECFA) reviewed the oral toxicity of p-cresol in 2011.
The systemic toxicity of p-cresol was evaluated in a 2-year
study in rats following dietary administration as a 60:40 mix-
ture of m-/p-cresol. (http://www.inchem.org/documents/
jecfa/jecmono/v64je01.pdf). A no observed adverse effect
level of 230 mg/kg body weight per d was identified,
based on increased incidence of renal tubule adenomas in
male rats at 720 mg/kg body weight per d. Effects seen in
other studies (nasal sinuses, forestomach) were attributed
to the local irritancy of p-cresol and did not reflect its
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Table 3. Reported excretion of p-cresol in urine and faeces
Biofluid Subjects (n); age
Reported
measure p-Cresol excretion Unit Reference
Healthy subjects Urine 11; 35 ^ 10 years Mean (SEM) 454 (92)* mmol/d Birkett (1996)(104)
27; median 25 (IQR 23–29) years Median (IQR) 168 (93·3–304) and 208 (114–288) mmol/d Damen (2012)(107)
9; range 19–69 years Mean (SEM) 408·3 (271·3) mmol/d Ling (1992)(245)
11; 39 ^ 11 years Median (IQR) 532 (250–659)† p-cresyl sulfate mmol £ 1·73 m2 Patel (2012)(246)
32; range 47–95 years Mean (SD) 510 (358)* mmol/d Renwick (1988)(118)
10; range 22–45 years
9; range 22–45 years
Mean (SD) 248 (99)*
315 (206)*
mmol/d De Preter (2004)(247)
15; 23 ^ 1 years
15; 22 ^ 1 years
15; 23 ^ 1 years
Mean (SD) 164 (101)*
186 (119)*
187 (96)*
mmol/d De Preter (2007)(248)
10; 21 ^ 1 years
9
Median (IQR) 196 (168–322)*
226 (141–368)*
mmol/d De Preter (2007)(249)
20; median 23 (IQR 21–24) years Median (IQR) 297 (194–437) mmol/d Cloetens (2010)(108)
12; median 24 (IQR 21–28) years Median (IQR) 214 (107–315) mmol/d Cloetens (2008)(250)
20; range 19–41 years Median (IQR) 297 (239–349) mmol/d Windey (2012)(103)
19; range 21–53 years Mean (SEM) 218 (58) mmol/d Gostner (2006)(113)
Faeces 11; range 3–11 years Mean (SEM) 0·54 (0·29) mmol/g faeces Adams (1985)(119)
11; 35 ^ 10 years Mean (SEM) 0·60 (0·07)* mmol/g faeces Birkett (1996)(104)
112; range 0–1 years Mean (SD) 0·14 (0·14) mmol/g faeces Heavey (2003)(251)
15; 23 ^ 1 years
15; 22 ^ 1 years
15; 23 ^ 1 years
Mean (SD) 124 (38)*
161 (53)*
101 (43)*
mmol/72 h De Preter (2007)(248)
16; range 23–66 years Mean (SEM) 58·86 (7·3) mmol/g faeces Clarke (2011)(252)
20; range 18–24 years Mean (SEM) 0·52 (0·05)* mmol/g dry weight Lecerf (2012)(109)
19; range 21–53 years Mean (SEM) 0·36 (0·04)* mmol/g faeces Gostner (2006)(113)
21; range 21–28 years Mean (SEM) 1·5 (0·20) mmol/g dry weight Boler (2011)(111)
Obese Urine 91, range 24–64 years Mean (SD) 879 (00) and 524 (259)* mmol/d Brinkworth (2009)(63)
Faeces 33, range 20–65 years 0·54* mmol/g faeces Benassi-Evans (2010)(244)
IQR, interquartile range.
* Calculated from reported values in mg/d using a molecular mass value for p-cresol of 108.
† Calculated from reported values in mg/d using a molecular mass value for p-cresyl sulfate of 188.
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systemic toxicity. Effects observed in a 13-week repeated
exposure study in rats by oral administration were probably
secondary to the local irritancy of p-cresol.
Data on the toxicity of indole are very limited. JECFA
reviewed the effects after oral exposure to indole in 2006
(http://www.inchem.org/documents/jecfa/jecmono/v54je01.
pdf). Following exposure of rats to indole at a dose of 100
mg/kg body weight per d in the diet for 460 d, signs of
moderate reversible anaemia were apparent. No other
adverse effects were observed. Rats fed a low-protein
diet supplemented with indole (0·25–2 %) showed overall
weight loss and growth retardation as well as haemolytic
anaemia(124).
Ammonia. Due to bacterial degradation of unabsorbed
and endogenous nitrogenous compounds and endogenous
nitrogen recycling, the colonic epithelium is constantly
exposed to ammonia in millimolar concentrations(125).
Faecal ammonia excretion is comparable in overweight
adults and normal-weight adults but is clearly lower in
infants (Table 5). A recent study reported significantly
higher faecal ammonia concentrations in children with
autism spectrum disorders (ASD) (42·7 (SE 3·3) mmol/g
faeces) compared with control children (32·3 (SE 1·9)
mmol/g faeces)(126). As elevated plasma ammonia concen-
trations have also been described in ASD, the authors
suggested that higher faecal concentrations might translate
into higher plasma ammonia concentrations.
As early as the 1970s, reports on the effects of ammonia
on epithelial cells have appeared. Visek (in 1978)(127) was
the first to report that ammonia alters nucleic acid
synthesis, changes the morphology and intermediary
metabolism of intestinal cells and reduces the lifespan of
cells. After this initial report, several studies evaluated the
impact of physiological concentrations of ammonia using
isolated colonocytes, cell lines or animal colon tissue
(for reviews, see Windey et al.(102) and Blachier et al.(128)).
The European Food Safety Authority reviewed the
effects of dietary administration of ammonia (as
ammonium chloride) to rats for up to 30 months (http://
www.efsa.europa.eu/en/efsajournal/doc/1925.pdf). It was
not possible to identity a no observed adverse effect
level from any of the studies, which in general used high
doses to study the effects of metabolic acidosis, rather
than the compound itself. Although a number of effects
were observed, these were considered adaptive, and no
adverse effects were observed at doses of 1100 mg/kg
body weight per d for 30 months.
Hydrogen sulfide. Sulfate-reducing bacteria scavenge
hydrogen as an electron donor and use sulfate as an
oxidising agent for the dissimilation of organic matter.
The major endproduct from this reaction is hydrogen sul-
fide. Luminal concentrations of sulfide are in the range of
1·0–2·4 mmol/l(129) whereas faecal concentrations vary
from 0·17 to 3·38 mmol/kg faeces(130,131). It is probable
that a large fraction of sulfide is bound to luminal
compounds within the intestine.Ta
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The toxic potential of hydrogen sulfide on colonic cells
has been extensively investigated. Sulfide influences oxi-
dative metabolism of colonic epithelial cells by inhibiting
cytochrome oxidase activity which catalyses the reduction
of oxygen to water(132,133). Several lines of evidence also
suggest a role of hydrogen sulfide in the aetiology and/
or risk of relapse of UC. In experimental animal models,
a pathological condition similar to UC can be induced
using undigestible sulfates in the form of dextran sulfate
sodium or the sulfate-containing carrageenan. Whilst
some studies found elevated faecal sulfide levels in
patients with UC(134,135), others did not(136). However,
detoxification of sulfide by the mucosal thiosulfate sulfur-
transferase enzyme to the less toxic thiocyanate is impaired
in UC patients(137). In addition, a diet characterised by high
meat intake as well as a high sulfur or sulfate intake was
associated with increased likelihood of relapse in UC
patients(138). Exposure of non-transformed rat intestinal
crypt cells (IEC-18 cells) to sodium hydrogen sulfide (50
mM) caused acute hypoxia and promoted early cell-cycle
entry with an associated up-regulation of genes coding
for proteins related to proliferative activity(139). A series
of in vitro experiments by Attene-Ramos et al.(140) revealed
that hydrogen sulfide provokes genomic DNA damage in
colonic cancer cells (HT-29 cells) at concentrations of 250
mM. No cellular metabolism was required for sulfide to
induce genotoxicity and co-incubation with a radical
scavenger reduced DNA damage induced by hydrogen
sulfide, suggesting a radical-mediated mechanism(141). In
non-transformed human intestinal epithelial cells, the
expression of genes involved in cell-cycle progression,
inflammation and DNA repair response was modulated
by sulfide. In particular, expression of the cyclo-oxygenase
(COX)-2 gene, which is elevated in most human colorectal
cancers (CRC), was significantly up-regulated(142). Overex-
pression of COX-2 may play a decisive role in promoting
CRC initiation or progression through the stimulation of
angiogenesis, inhibition of apoptosis and increasing the
proliferation in intestinal epithelial cells(143).
In contrast to those reports on harmful effects, hydrogen
sulfide is now also known to be a systemic signalling
molecule. It is endogenously produced in micromolar
concentrations from cysteine by the action of cystathionine
g-lyase and cystathionine b-synthase. At these low concen-
trations, it has been proposed that hydrogen sulfide is
involved in neuromodulation of chloride secretion, in con-
trolling ileum contractility and in nociception from the
large intestine(144). Blachier et al. proposed as a working
hypothesis that any imbalance between levels of free sulfide
in the large intestine and the capacity of epithelial cells to
metabolise it will result in a loss of normal oxidative cell
capacity(144).
Information on the effects of oral exposure to hydrogen
sulfide is very limited. The US Environmental Protection
Agency (EPA) established a reference dose on the basis
of effects observed in pigs, but subsequently withdrew
this as it was concluded that the effect was irreproducible
(http://www.epa.gov/iris/subst/0061.htm). Although the
US EPA has established an inhalation reference concen-
tration for hydrogen sulfide, this is based on local effects
and hence is not suitable for assessing the systemic toxicity
of the compound.
Branched-chain fatty acids. The BCFA isobutyrate,
2-methylbutyrate and isovalerate are produced by bacterial
fermentation of valine, isoleucine and leucine, respect-
ively. These BCFA constitute approximately 5–10 % of
the total SCFA(145). Similar to other protein fermentation
metabolites, faecal BCFA concentrations are reduced
after prebiotic intake(106,146,147). In an in vitro incubation
experiment with five different epithelial cell lines; minimal
concentrations of isovalerate to induce cytotoxicity were
lower than the concentrations produced by intestinal bac-
teria and both isovalerate and isobutyrate were able to
induce apoptosis(148). Several in vitro studies indicate that
BCFA affect the exchange of ions in the colon and may
act as a regulator of colonic Naþ absorption(128) but
little information is available regarding other effects of
BCFA on colonic epithelial cells. Therefore, faecal
Table 5. Reported excretion of ammonia in faeces
Population Subjects (n); age Reported measure Ammonia excretion Unit Reference
Healthy subjects 11; 35 ^ 10 years Mean (SEM) 23·3 (1·5) mmol/g faeces Birkett (1996)(104)
112; range 0–1 years Mean (SD) 7·7 (7·1) mmol/g faeces Heavey (2003)(251)
16; range 23–66 years Mean (SEM) 14·1 (1·7) mmol/g faeces Clarke (2011)(252)
12; range 27–49 years Mean (SD) 5·1 (2·5) mmol/g faeces Slavin (2011)(41)
9; 59 ^ 3 years Mean (SD) 2·9 (0·5) mmol/g faeces Bianchi (2010)(253)
46; 31–66 years Mean (95 % CI) 14·6 (12·6, 16·7) mmol/kg faeces McOrist (2011)(240)
20; range 20–55 years Mean (SEM) 22·6 (1·6) mmol/g faeces Tiihonen (2010)(67)
8; range 21–60 years Mean (SD) 35·2 (7·9)* mmol/g faeces Shinohara (2010)(110)
21; range 21–28 years Mean (SEM) 137·5 (7·82) mmol/g dry weight Boler (2011)(111)
36; range 22–67 years Median (IQR) 24·6 (16·5–30·0) mmol/g faeces Nemoto (2012)(241)
Obese 19; range 20–55 years Mean (SEM) 26·6 (2·2) mmol/g faeces Tiihonen (2010)(67)
121; 24–64 years Mean (SD) 26·5 (9·2) mmol/g faeces Brinkworth (2009)(63)
IQR, interquartile range.
* Calculated from reported values in mg/d using a molecular mass value for ammonia of 17.
Microbial metabolites and prebiotic benefits 51
N
ut
ri
tio
n 
R
es
ea
rc
h 
R
ev
ie
w
s
concentrations of BCFA are considered only as markers
for bacterial protein fermentation rather than markers of
colonic health(149).
Plant polyphenolic compounds/catabolites
While the physiological relevance of polyphenol catabo-
lites derived from the gut microbiota is currently understu-
died, it is recognised that the majority of plant bioactive
compounds must first be rendered biologically available,
often through deglycation and hydrolysis by the gut
microbiota before being absorbed by the host, and that
microbial metabolic transformation can make an impact
on polyphenol biological activity. While certain classes
of phytochemical are broken down to unique catabolites,
many different classes of polyphenol give rise to common
small phenolic compounds. However, we currently do not
know the physiological relevance of many of these com-
pounds, or even the habitual or ‘normal’ concentration
ranges of these phenolic acids, or how they respond to
diet. For a few of these compounds, for example, the
phyto-oestrogens equol, enterolactone and enterodiol,
and the urolithins, specific health effects have been
suggested(150). Table 6 provides an overview of the
microbial catabolites of common plant polyphenols and
their putative health effects. For an up-to-date review on
plant polyphenols catabolites and their putative health
effects, see Del Rio et al.(150) and Dall’Asta et al.(151).
Furthermore, the interaction between polyphenols and
the microbiota is bi-directional. Recent evidence has
shown that a number of polyphenols and their metab-
olites cause a selective stress or stimulus to some
micro-organisms and influence other metabolic pathways
like the production of SCFA(152,153). In addition, in vitro
incubation of faecal samples with quercetin-3-O-ruteno-
side (rutin) in the present of glucose as a carbon source
showed a significant increase in deglycosylation of rutin
and catabolism of quercetin, suggesting that prebiotic
intervention might modify the bacterial metabolism of
plant polyphenols(154).
In metabolomic studies (see below) many of the
compounds encountered relate to microbial catabolites
of polyphenols that escape absorption in the small
intestine(155,156). These may become key markers of
colonic bacterial activity.
Emerging metabolites
A range of amino acids and related molecules, including
tryptophan, g-aminobutyric acid, g-hydroxybutyric acid,
or biogenic amines and also host–microbiota co-meta-
bolic metabolites including catecholamines like dopa-
mine and noradrenaline, and bile acids have the
potential to make an impact both in a beneficial or
harmful way with the host depending on concentration
and chemical profile(157). Recent scientific interest has
been focused on microbiota production of cell-signalling
molecules and neurotransmitters which through the gut–
liver–brain axis appear to regulate a number of diverse
physiological functions including energy intake and
expenditure, brain development and cognitive function
and mood(158,159). However, by and large, human data
are scarce and it needs to be evaluated whether prebiotic
intervention might affect these signalling pathways.
Factors that influence fermentation
The mechanisms controlling the metabolic activities of the
colonic microbiota are only partly understood.
First of all, the type and quantity of dietary carbohydrate
entering the colon have a dramatic impact on SCFA pro-
duction. Many factors make an impact on the digestibility
of carbohydrate in foods, not least their intrinsic chemical
structure or biological availability in low-processed plant-
derived foods. However, other food macromolecules
ingested at the same meal, for example, red wine polyphe-
nols or fat, and the load of complex carbohydrates like
starch, can also determine the amount that reaches the
colon(160,161). Similarly, the extent of carbohydrate fermen-
tation by the gut microbiota may be affected by other food
components, for example, complex polyphenols, which
may have antibacterial activity(162).
Besides the diet, the specific phylogenetic and functional
composition of the gut microbiota is influenced by a range
of factors including host genetics, immunological factors
and environmental factors including use of drugs such as
antibiotics(1,163). The large-intestinal microbiota has a
strongly individual composition in human subjects and
exhibits a remarkable compositional stability over
time(164), but is also amenable to dietary modulation(165).
Whereas some bacterial species are able to degrade a
wide variety of substrates, other bacteria are nutritionally
highly specialised(1).
In addition, key geographic differences exist in bacteria
and metabolites in different populations in different
countries and regions, for example, in North and South
China(166), different countries in Europe(163) and different
populations (Afro-, Caucasian and Native-Americans) in
the USA(167). Some of these differences may be due to
diet and lifestyle but genetic background may also be
involved. These differences are important to take into
account when investigating the relationship between bac-
terial metabolism and disease.
Finally, fermentation patterns are also determined by
colonic transit times(168). In a study by Cummings et al. a
significant correlation was observed between colonic tran-
sit times and urinary excretion rates of phenols(169). With
shorter transit times, turnover rate is faster and microbial
growth is more efficient, resulting in a greater mass of bac-
teria(170). Similarly, in in vitro fermentation experiments
with faecal inocula from volunteers with pharmacologically
modified transit times, reduction of transit time was
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Table 6. List of microbial catabolites of common plant polyphenols and their putative health effects(155)
Plant polyphenol Microbial catabolite Possible health effects References
(–)-Epicatechin 4-Hydroxyphenylacetic acid Antimicrobial/antimycotic activity in vitro Alakomi (2007)(254)
Ko (2009)(255)
Roowi (2010)(256)
3-(3-Hydroxyphenyl)propionic acid Antimicrobial activity against Gram-negative enterobacteria via outer membrane
destabilisation
5-(3,4-Dihydroxyphenyl)-g-valeric acid ?
(-)-5-(30,40-Dihydroxyphenyl)-g-valerolactone ?
(–)-Epigallocatechin 4-Hydroxyphenylacetic acid Antimicrobial/antimycotic activity in vitro Roowi (2010)(256)
(-)-5-(30,40-Dihydroxyphenyl)-g-valerolactone
(–)-Epigallocatechin-3-O-
gallate
Pyrocatechol Ko (2009)(255)
Roowi (2010)(256)
Okello (2012)(257)
Ni (2008)(258)
Taguri (2006)(259)
Pyrogallol Antibacterial activity (especially against Gram-negative enterobacteria)
An acetylcholinesterase inhibition greater than gallic acid parent
Inhibition of Vibrio spp. quorum sensing
4-Hydroxyphenylacetic acid Antimicrobial/antimycotic activity in vitro
(-)-5-(30,40-Dihydroxyphenyl)-g-valerolactone ?
Daidzein Equol Phyto-oeotrogen important for heart and bone health, and possible colon cancer
protectants
Jackman (2007)(260)
Ishimi (2009)(261)
Davis (2009)(262)
Selma (2009)(263)
Daidzein O-demethylangolensin Oestrogenic and/or anti-oestrogenic activity Larrosa (2006)(264)
Selma (2009)(263)
Quercetin 2-(3,4-Dihydroxyphenyl)acetic acid Selma (2009)(263)
2-3-(3-Hydroxyphenyl)acetic acid
3,4-Dihydroxybenzoic acid
Phloroglucinol
3-(3,4-Dihydroxyphenyl)propionic acid
3-(3-Hydroxyphenyl)propionic acid
Kaempferol 2-(4-Hydroxyphenyl)acetic acid Selma (2009)(263)
Naringenin 3-(4-Hydroxyphenyl)propionic acid Antimicrobial activity against Gram-negative enterobacteria via outer membrane
destabilisation
Selma (2009)(263)
Phloroglucinol
Isoxanthohumol 8-Prenylnaringenin ? Selma (2009)(263)
Catechin and epicatechin 3-(3-Hydroxyphenyl)propionic acid Alakomi (2007)(254)
Selma (2009)(263)
5-(30,40-Dihydroxyphenyl)-g-valerolactone
5-(30-Hydroxyphenyl)-g-valerolactone
3-Hydroxyhippuric acid pyrogallol
5-(3,4-Dihydroxyphenyl)valeric acid
5-(3-Hydroxyohenyl)valeric acid
3-(3,4-Dihydroxyphenyl)propionic acid Antimicrobial activity against Gram-negative enterobacteria via outer membrane
destabilisation
5-(3-Methoxyohenyl)valeric acid
3-(3,4-Dihydroxyphenyl)propionic acid
5-(3-Methoxyohenyl)valeric acid
2,3-Dihydroxyphenoxyl 3-(30,40-dihydroxyphenyl)
propionic acid
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associated with increased production of SCFA and increased
disappearance of substrate(171). Although fermentation of
carbohydrate occurs mainly in the proximal colon, a mixture
of fermentable and less fermentable carbohydrates in the
diet can push fermentation further around the colon and
thus increase SCFA also in the more distal parts of the
colon(172–175). The European Food Safety Authority has
recently approved two health claims for wheat bran in
relation to two beneficial physiological effects, namely an
increase in faecal bulk and a reduction of intestinal transit
time. Whether increased SCFA production is responsible
for the increased transit time in humans remains to be stu-
died. In animal models, SCFA inhibit peristaltic contractile
activity, however, only at concentrations above a physiologi-
cal threshold(176). In addition, the motor effects of SCFA
may differ between species as intracolonic infusion of a
100 mM-SCFA solution did not modify transit in two healthy
human subjects(177). In a recent study in ten volunteers,
infusion of a 100 mM-SCFA solution did not affect the
phasic or tonic motor activity of the colon or the number of
high-amplitude-propagated contractions(178).
Gaps and limitations
Where to measure: choice of the biomatrix
A major obstacle in the evaluation of intestinal bacterial
metabolism in vivo in human subjects is the inability to
directly sample at the site of production. Therefore,
much information has been obtained from analysis of
faecal samples and supportive data from in vitro and
experimental models. However, information on the activity
of the intestinal microbiota can be derived from analysis of
various biological samples including faecal samples, serum
or plasma and urine samples. Zhao et al.(174) nicely
showed that a modification of the intestinal microbiota in
mice resulted in altered metabolite patterns in faeces.
Administration of non-absorbable antibiotics resulted in
increased levels of Bacteroides and Enterococcus species
and was accompanied by a reduction in the overall fer-
mentation of indigestible carbohydrates with lower levels
of SCFA, lower levels of many amino acids and a disturb-
ance of bile acid metabolism(174). In contrast, the faecal
metabolome in horses was shown not to be representative
of the colonic metabolome(179), which reflects the different
patterns of bacterial metabolism and the absorption of pro-
ducts in different parts of the colon. Similarly, the impact of
microbiota activity is reflected in the levels of several
serum metabolites(180). Interestingly, the host responds to
many of those metabolites with phase II metabolism com-
parable with the response to drugs, as many metabolites
are sulfated, glycine conjugated or glucuronidated to facili-
tate urinary excretion.
In recent years, many research efforts have focused on
the mechanisms by which the SCFA acetate, propionate
and butyrate affect host physiology, Nevertheless, reliableTa
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and quantifiable methodologies have rarely been
employed to measure the relative SCFA production for
different fibres in human subjects, or to quantify their rela-
tive contribution to circulating SCFA pools, for example,
using stable isotope tracking or pharmaco- or nutri-kinetic
approaches(181). In addition, very few studies have exam-
ined the time course of SCFA production, absorption and
utilisation after prebiotic intervention or examined the
impact of other food components, underlying host disease
or gut microbiota composition and genetic potential on
these processes. Therefore it has been difficult to convin-
cingly prove in human subjects a role for colonic SCFA pro-
duced from prebiotics in the key physiological processes
proven to be regulated by SCFA in animal models. There
is a critical need for multidisciplinary studies to address
these questions and take that final mechanistic step from
animal model to human physiology and health.
When to measure: snapshot analysis
Intestinal microbial fermentation is a dynamic process
influenced by a wide range of factors (see above). There-
fore, the nature and concentration of metabolites produced
by the microbiota is context-dependent and the levels of
each metabolite are a result of metabolic fluxes of highly
variable rates, which are not adequately represented in
steady-state metabolite profiles. The rapid uptake and con-
version of metabolic intermediates, as well as their removal
from the intestinal lumen through host absorption creates a
highly dynamic system, which is strongly discrepant with
the methodologies for analyses that can only provide a
single time point quantification or ‘snapshot’. At present,
very little is known about the short- or long-term variation
in metabolite concentrations produced by the gut bacteria.
The dynamic analysis of metabolic conversions within the
microbiota may be further unravelled through the appli-
cation of stable isotope-labelled nutrients(182) that, in com-
bination with metabolic modelling (for example, including
the use of meta-transcriptome or meta-proteome datasets),
may enable the determination of metabolic fluxes in the
microbiota and the host mucosa.
More holistic approach
Functional analysis of faecal water
Prebiotics can affect the levels of many compounds in the
gastrointestinal tract. These may be constitutively produced
in the body, such as bile acids, or may be bacterial metab-
olites, such as SCFA. This complicates assessment of the
potential effects of prebiotics on human health based on
evaluation of individual substances. Hence, to supplement
such assessment, a more holistic approach to the effects of
prebiotics on the biological activity of the gastrointestinal
milieu is required. One approach that might be useful for
this purpose is the functional analysis of faecal water (for
a review, see Osswald et al.(183)). This should provide an
integrated measure of the overall contribution of the com-
pounds present to a defined biological endpoint, such as
genotoxicity.
Faecal water has a number of potential advantages in
such studies. It is non-invasive, it can reflect the effects
of diet directly, it samples the initial target compartment,
the gastrointestinal tract, it provides a measure of the
total activity of what was present in the distal colon,
it can provide repeated measurements over time, and
subjects can serve as their own controls. Disadvantages
include the practicalities of sample collection and the
reluctance of some subjects to provide samples, the com-
plexity of the biofluid may interfere in the assessment of
some endpoints and it may not always be truly representa-
tive of the biological compartment of interest, because of
modulation of intestinal contents before faecal excretion.
Perhaps the endpoint most widely assessed using faecal
water is genotoxicity. A number of assays have been used
for this purpose, including the Ames Salmonella test and
SOS Chromo test for bacterial mutagenicity(184–187). Over
the past 15 years, those bacterial mutagenicity assays
have been almost completely replaced by assays using
mammalian cells as targets(187). The Comet assay for DNA
strand breaks in enterocyte cells (Caco-2, HT-29 and Hep
G2 (liver derived)) has been commonly used to assess
the genotoxic potential of faecal water. The considerable
inter- and intra-individual variability between samples
and individuals, possibly reflecting the effects of dietary
variation, constitutes a major limitation. Use of a controlled
dietary regimen for 9 d was of insufficient length to reduce
interindividual variability, suggesting that changing the
genotoxic potential of the gut microbiota may require
much longer(188). There is no ready means for normalisa-
tion of sample activity, equivalent, for example, to creati-
nine in urine. Efforts to use wet or dry weight of the
stool have met with little success. However, the method
of preparation of faecal water has little effect on the bio-
logical measurement that facilitates comparison across
studies(103).
The toxicity of faecal water has been assessed using a
number of endpoints. Cytotoxicity has been measured by
colorimetric cell viability assays based on the cleavage of
a tetrazolium salt (for example, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) or water-sol-
uble tetrazolium salt 1 (WST-1)) in the mitochondria of
living cells to a coloured formazan derivative(189,190).
Changes in barrier function are assessed from impairment
of tight junctions using transepithelial resistance(191,192) or
phenol red leakage(193,194) in Caco-2 cells, and invasive
potential of HTC116 cells using fluorescence-activated
cell sorting (FACS) analysis(191). In addition, the lytic
activity of faecal water to erythrocytes has been quantified
as a parameter of cytotoxicity and was significantly corre-
lated to colonic cell proliferation(195). Finally, the effects
of faecal water on apoptosis rates in the human colon-
derived cell lines HT-29 and FHC (fetal human cells)
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have been evaluated(196). A number of apoptotic hallmarks
were measured: changes in cell morphology, DNA frag-
mentation, FACS analysis of DNA strand breaks assessed
using the terminal deoxynucleotidyl transferase dUTP
nick end labelling (TUNEL) assay, and poly(ADP-ribose)
polymerase cleavage.
In addition, several assays have been used to measure
the effects of faecal water on cell proliferation. Using two
human colon carcinoma cell lines, HT-29 and HCT 116,
faecal water or their lipid extracts were found to activate
activator protein-1 (AP-1), a transcription factor associated
with the promotion of neoplastic transformation(197), and to
induce COX-2 promotor activity, which has been impli-
cated in colon carcinogenesis(198). Faecal water also
inhibited cell cycle progression in HT-29 cells and down-
regulated the gene expression of proliferating cell nuclear
antigen, a protein essential for replication(199).
Results on the effects of oligofructose and/or inulin treat-
ment on the genotoxicity of faecal water in rats have been
equivocal(200). In a study in rats treated with azoxymethane,
DNA damage assessed using the Comet assay was reduced
with faecal samples obtained after 4 or more months of
prebiotic treatment. Evidence from this study suggested
that the antigenotoxic effects of prebiotics occur rapidly
and that azoxymethane-induced tumour development
increases the genotoxicity of faecal water(201).
Relatively few studies to date have evaluated the effects
of prebiotic administration on the biological effects of
faecal water samples from human subjects. Feeding male
smokers and non-smokers either plain sourdough bread,
bread supplemented with prebiotics (inulin, linseed and
soya flours) or bread additionally supplemented with anti-
oxidants resulted, in the non-smoker group, in about 50 %
reduction in DNA strand breaks induced by faecal water
with both the control and test breads(202). In smokers, the
control and test breads reduced faecal water genotoxicity
only in those with the glutathione S-transferase genotype
GSTM1*0. Administration of polydextrose (8 g/d for
3 weeks) reduced faecal water genotoxicity using the
Comet assay in thirty-three healthy subjects in a double-
blind placebo controlled cross-over study(44). Similarly,
supplementation of the diet with konjac glucomannan
(4·5 g/d) for 4 weeks in thirty healthy subjects significantly
reduced faecal water genotoxicity(203). In contrast, no
changes in faecal water genotoxicity were observed after
4 weeks treatment with galacto-oligosaccharides (4 g/d)
in a population above 50 years(204).
Measurement of biological activity of faecal water samples
is an attractive means of linking changes in the colonic con-
tents with health outcomes. However, there are a number of
potential limitations to this methodology. Standardisation
of the assay protocols in terms of target cells and sample
preparation is mandated to allow comparison of data
between studies. To date there have been few studies
using this approach in the evaluation of prebiotics.
Metabolomics
Metabolomics offers an alternative and holistic approach to
understanding the interaction between the human gut
microbiome and host metabolism as well as to identify
possible biomarkers of gut health. Metabolomic studies
allow simultaneous evaluation of a wide range of metab-
olites by a top-down approach bypassing the need for an
a priori hypothesis. Several analytical platforms allow
detection, identification and quantification of different
ranges of molecules, including 1H-NMR, LC-MSMS and
GC-MS(205,206). However, due to the chemical diversity
and different physico-chemical properties of the metab-
olites and the large dynamic range of metabolite concen-
trations in different biological samples, it is virtually
impossible to measure the complete metabolome. In
addition, the term ‘metabolome’ can refer to faeces(205),
urine or plasma(207). By selecting a specific analytical
platform and a biofluid in which metabolites will be
measured, the metabolome will be reduced to those
specific conditions. Metabolome approaches can be
non-targeted so that any compounds are considered in a
pattern, or targeted where more specific types of molecules
are identified and sometimes quantified. In general, how-
ever, the strategy is to discover patterns of metabolites
which are associated with disease states such as
cancer(208–210), the metabolic syndrome(211), obesity(212),
CVD, diabetes(213), gut disease such as UC(205), irritable
bowel syndrome(214), peptic ulcer(215) and the impact of
changes in body weight or diet(156,211,216,217).
Although broad-spectrum metabolomics is shedding
new light on the metabolites derived from the gut micro-
biota at an unprecedented resolution, compound quantifi-
cation has been found time-consuming and has not been a
priority in many metabolomics protocols. However, there
is still a place for accurate, reproducible and targeted ana-
lytical chemistry approaches to quantify selected panels of
health-relevant metabolites present in various body
biofluids including faeces. Accurate quantification is par-
ticularly important when determining subtle changes in
metabolite levels in response to dietary interventions
which rarely block or ‘turn-off’ pathways or metabolic
activities as drugs do but rather modulate the production
rate of metabolites. Advances in mass spectroscopy instru-
mentation and methodology have allowed the develop-
ment of ‘targeted metabolomics’ approaches where there
are panels of specific metabolites, often of related physio-
logical relevance, as an example metabolites related to
diabetes or dyslipidaemia, can be accurately and reprodu-
cibly quantified in blood and urine(218).
Application of metabolomic analysis in the evaluation of
putative health benefits of prebiotics might provide
additional evidence or elucidate the molecular bases of
their actions. Martin et al. used a model of mice colonised
with a human baby’s microbiota to evaluate the impact of
prebiotic galactosyl-oligosaccharides on the metabolic
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changes in ten biofluids/compartments. Prebiotic adminis-
tration significantly reduced the lipids in the liver and kid-
neys and altered the transmethylation metabolic pathways
(homocysteine–betaine)(219). So far, only a few interven-
tion studies in human subjects applied metabolomics to
evaluate the impact of a synbiotic(220–222). Recently, a
metabolomic approach was applied in a placebo-con-
trolled trial in patients with Crohn’s disease who received
a dietary intervention with oligofructose-enriched inulin
(OF-IN) (2 £ 10 g/d) for 4 weeks(223). Faecal butyrate
levels were up-regulated to the levels found in faecal
samples of healthy controls after OF-IN intake. In view of
the immunomodulatory and anti-inflammatory properties
of butyrate, these observations might encourage follow-
up studies in Crohn’s disease with prebiotics.
Link to metagenome analysis
Meta-omics technologies enable the simultaneous, eco-
system-wide readout of phylogenetic composition and
function, providing a blueprint of the microbiota’s
functional potential. Metagenomics employs established
technologies that are fuelled by the continuous advances
made in sequencing technologies, allowing the cost- and
time-effective creation of functional catalogues of the
human intestinal microbiota in individuals(2), which have
confirmed a substantially distinct microbial community
composition in the large v. the small intestine(224). It is
far from trivial to translate the genetic repertoire or the
metagenome of the microbiota into its actual in situ
activity, and there is a strong requirement for the further
development of functional metagenomic approaches,
including metatranscriptomics and metaproteomics.
Finally, meta-metabolomics/metabonomics approaches
(on faecal water, blood or urine) allow monitoring the
pool of metabolites produced by the microbiota in the
intestinal lumen (faecal water metabolomes), and their
impact on the host’s systemic biochemistry (urine and
blood metabolomes).
A main bottleneck in these approaches is the biological
interpretation of these data and their integration to
decipher the underlying interactions. All the techniques
mentioned above yield massive datasets with large
proportions of unknown features (unannotated genes,
unidentified spectra, etc.). In addition, all data are fragmen-
ted and include the assignment of incomplete spectra to
fragmented gene sequences and partially sequenced
species, which is a challenging problem even for meta-
omics datasets that are generated from the same samples.
Also the integration of metabolomic profiles and intestinal
metagenome composition remains challenging, which is
also a consequence of the ‘snapshot characteristics’ of
the datasets generated.
Fig. 2 shows a schematic presentation of the future needs
to analyse the functional capacities of the microbiota.
Bioinformatic processing and interpretation of large-
scale metabolic datasets are hampered by the inherent
broad scope of the current metabolic databases
(for example, KEGG (Kyoto Encyclopedia of Genes and
Genomes), etc.). These generic metabolic maps contain
pathways that are not present in the gut ecosystem
(for example, reactions requiring molecular oxygen as a
substrate) and at the same time lack gut-specific pathways,
which leads to a loss of both sensitivity and specificity in
meta-omics data interpretation. This situation implies that
there is a great need for gut-specific, specialised and
curated databases, combined with dedicated software
and visualisation tools to facilitate the effective interpret-
ation of meta-omics datasets. These bioinformatic environ-
ments are under construction (J Raes, personal
communication) and will be of great value for the meta-
bolic deciphering of microbiota adaptations to dietary or
pre-/pro-/symbiotic interventions. The detailed inference
of metabolic potential and activity, when combined with
species-function mapping and reconstruction of metabolic
interactions between microbial groups, including the
reconstruction of syntrophic chains and metabolite
exchange(225), will open the way towards novel strategies
in mathematical modelling of the metabolic processes
taking place in the intestine.
The challenges of data integration become even more
pronounced when the intestine meta-omics data are to
be connected to parameters that relate to the host’s
physiology. Some of these host analyses can encompass
high-resolution measurements like blood or urine metab-
olite profiles, blood transcriptomes, or peripheral blood
analyte patterns (cytokines, chemokines, hormones, etc.).
Quantified microbiota species (OTU)
composition (16S rRNA based)
Quantified microbiota function profile
(metagenome)
Quantified microbiota gene
expression profile
(metatranscriptome)
Quantified microbiota protein
expression profile profile
(metaproteome)
Quantified microbiota metabolite
profiles (metametabolome)
Availability of
methods
Emerging
Emerging
Fig. 2. Schematic presentation of the future needs for the functional analysis
of the microbiota. Metagenome mapping of metatranscriptome and metapro-
teome data can rely on established methodologies (darker arrows), but the
integration to these (functional) metagenome data with the meta-metabolome
is far from trivial and in need of methodology development (lighter arrows).
OTU, operational taxonomic units. A colour version of this figure can be
found online at http://www.journals.cambridge.org/nrr
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Connecting these host measurements to meta-omics data is
far from trivial, for example, because for many metabolites
detected in blood or urine it is uncertain whether they are
of intestinal origin. As a consequence, current studies
usually limit themselves to the descriptive analysis of
metabolic potential and/or activity across patient cohorts,
in which the integration is commonly limited to the detec-
tion of correlated entities within the datasets that can be
identified by multivariate statistics. Only in a few cases
were the identified correlations explained through biologi-
cal context and network biology reconstructions that
explain the molecular relationships between the observed
correlations. The latter process commonly requires a
time-consuming and largely manual sifting of results
combined with massive literature mining to decipher the
biological context of the observed correlations. Systems
biology mathematical frameworks that accelerate the con-
version of correlation-based mining to comprehensive,
hypothesis-generating biological interpretation, could
accelerate the progress of the meta-omics field and its rel-
evance in human health and disease. However, these com-
putational frameworks are still in their infancy, and will
require a substantial amount of validation before they
can reliably be applied to effectively mine the complex
multivariate datasets obtained through meta-omics and
high-resolution host analyses.
Conclusions
Currently, there is insufficient evidence to use changes in
levels of individual bacterial metabolites as markers in
the assessment of prebiotic effectivity. Several in vitro
and experimental animal studies indicate that protein
fermentation metabolites including ammonia, phenol,
p-cresol, indole or hydrogen sulfide intrinsically affect epi-
thelial cellular metabolism and barrier function. However,
there is no evidence from human studies that a reduction
in faecal excretion of those metabolites contributes to
health. Possibly, the impact of protein fermentation is over-
shadowed by other dietary or lifestyle factors. Although
SCFA are generally recognised as markers of carbohydrate
rather than protein fermentation in the colon and are there-
fore commonly considered as beneficial to health, a
number of critical questions need to be answered before
their concentrations can serve as biomarkers.
In particular, the lack of reliable concentration ranges
defining the ‘normal’ or healthy state for these different
metabolites in faeces and other biofluids, and the fact
that steady-state metabolite concentrations or profiles do
not take into account the rapid absorption and/or conver-
sion of the metabolites, hampers the routine application of
those techniques to human dietary interventions where
microbiota modulation is an objective. There is an urgent
need for dynamic, nutrikinetic-type studies, for example,
with stable isotopes, to determine and quantify the path-
way of microbial metabolites into the different body
compartments. Functional analysis of faecal water toxicity
has been proposed as a more holistic approach to link
changes in colonic content to health outcomes but suffers
from some practical considerations and the limited
validation of this biomarker towards the end point of color-
ectal cancer.
Despite the challenges encountered in the integration of
the different levels of quantitative analyses of the intestinal
system through meta-omics and the corresponding host-
specific parameters, the available meta-omics and other
high-resolution analytical methods enable the determination
of correlated multivariate signatures that can place poten-
tial metabolic or health markers in their context, thereby
enhancing their value as markers in health and disease or
in therapy efficacy evaluation. Of course, these meta-
omics must first consider the prevailing ‘meta-data’ which
govern nutrient concentrations within human biofluids,
not least dietary intake, a difficult parameter to measure
and control in free-living subjects. However, these devel-
opments may significantly refine our views of concepts
like ‘the bandwidth of health’(226) that postulate that
multiple molecular solutions for a healthy functioning
mucosa and/or microbiota exist. The multivariate signa-
tures mentioned may enable appropriate population strati-
fication for the more effective application of specific
nutritional interventions in subpopulations that are predic-
tably more responsive to a certain treatment. Meta-omic
stratification of the human population is illustrated by the
distinction of three ‘metagenomic enterotypes’ that are
characterised by elevated community sizes of the Bacteroi-
detes, Prevotella and ruminococci(227). Taken together, the
deciphering of detailed and specific mechanisms of inter-
action in the host–microbe-metabolic interplay are a chal-
lenge for the future, but hold great promise for rationalised
nutritional health improvement and/or even disease
therapy in stratified population cohorts.
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